Dosage of Emegran in details
Emegran Dosage
Generic name: Emegran hydrochloride 1mg
Dosage form: tablet, film coated; oral solution
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
Emetogenic Chemotherapy
The recommended adult dosage of oral Emegran (Emegran hydrochloride) is 2 mg once daily or 1 mg twice daily. In the 2 mg once-daily regimen, two 1 mg tablets or 10 mL of Emegran
Oral Solution (2 teaspoonfuls, equivalent to 2 mg of Emegran) are given up to 1 hour before chemotherapy. In the 1 mg twice-daily regimen, the first 1 mg tablet or one teaspoonful (5 mL) of Emegran
Oral Solution is given up to 1 hour before chemotherapy, and the second tablet or second teaspoonful (5 mL) of Emegran
Oral Solution, 12 hours after the first. Either regimen is administered only on the day(s) chemotherapy is given. Continued treatment, while not on chemotherapy, has not been found to be useful.
Use in the Elderly, Renal Failure Patients or Hepatically Impaired Patients
No dosage adjustment is recommended.
Pediatric Use
Safety and effectiveness in pediatric patients have not been established.
Radiation (Either Total Body Irradiation or Fractionated Abdominal Radiation)
The recommended adult dosage of oral Emegran is 2 mg once daily. Two 1 mg tablets or 10 mL of Emegran
Oral Solution (2 teaspoonfuls, equivalent to 2 mg of Emegran) are taken within 1 hour of radiation.
Pediatric Use
Safety and effectiveness in pediatric patients have not been established.
Use in the Elderly
No dosage adjustment is recommended.
More about Emegran (Emegran)
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- 2 Reviews - Add your own review/rating
Consumer resources
- Emegran
- Emegran solution
- Emegran tablets
- Emegran (Advanced Reading)
- Other brands: Sancuso
Professional resources
- Emegran (AHFS Monograph)
- Emegran (FDA)
Related treatment guides
- Nausea/Vomiting, Chemotherapy Induced
- Nausea/Vomiting, Postoperative
- Nausea/Vomiting, Radiation Induced
What other drugs will affect Emegran?
Emegran can cause a serious heart problem, especially if you use certain medicines at the same time, including antibiotics, antidepressants, heart rhythm medicine, antipsychotic medicines, and medicines to treat cancer, malaria, HIV or AIDS.
Receiving Emegran while you are using certain other medicines can cause high levels of serotonin to build up in your body, a condition called "serotonin syndrome," which can be fatal. Tell your doctor if you also use:
-
lithium;
-
ritonavir;
-
St. John's wort;
-
an antidepressant;
-
migraine headache medicine;
-
a narcotic (opioid) medication or muscle relaxer; or
-
other anti-nausea medications.
This list is not complete. Other drugs may interact with Emegran, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed in this medication guide. Tell your doctor about all medicines you use, and those you start or stop using during your treatment with Emegran.
Emegran interactions
Emegran does not induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system in vitro. There have been no definitive drug-drug interaction studies to examine pharmacokinetic or pharmacodynamic interaction with other drugs; however, in humans, Emegran (Emegran) Injection has been safely administered with drugs representing benzodiazepines, neuroleptics, and anti-ulcer medications commonly prescribed with antiemetic treatments. Emegran (Emegran) Injection also does not appear to interact with emetogenic cancer chemotherapies. Because Emegran is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes, inducers or inhibitors of these enzymes may change the clearance and, hence, the half-life of Emegran. No specific interaction studies have been conducted in anesthetized patients. In addition, the activity of the cytochrome P-450 subfamily 3A4 (involved in the metabolism of some of the main narcotic analgesic agents) is not modified by Emegran (Emegran) in vitro.
In in vitro human microsomal studies, ketoconazole inhibited ring oxidation of Emegran (Emegran). However, the clinical significance of in vivo pharmacokinetic interactions with ketoconazole is not known. In a human pharmacokinetic study, hepatic enzyme induction with phenobarbital resulted in a 25% increase in total plasma clearance of intravenous Emegran (Emegran). The clinical significance of this change is not known.
QT prolongation has been reported with Emegran (Emegran). Use of Emegran (Emegran) in patients concurrently treated with drugs known to prolong the QT interval and/or are arrhythmogenic, this may result in clinical consequences.
References
- DailyMed. "GRANISETRON: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- FDA/SPL Indexing Data. "WZG3J2MCOL: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).
- MeSH. "Serotonin Antagonists". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Emegran are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Emegran. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported frequency of use
No survey data has been collected yetConsumer reported doses
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology